Biogen (BIIB)
(Delayed Data from NSDQ)
$211.17 USD
-16.27 (-7.15%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $210.00 -1.17 (-0.55%) 5:50 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
BIIB 211.17 -16.27(-7.15%)
Will BIIB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIIB
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: SAGE Plunges on Study Failure, AGEN Down on Regulatory Update & More
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
Other News for BIIB
NEW YORK MARKET CLOSE: Stocks fly, ending fraught week with a flourish
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
AbbVie exits Alzheimer’s program on lack of differentiation
European committee says Alzheimer's treatment Leqembi shouldn't get marketing approval